scispace - formally typeset
Journal ArticleDOI

Natural product and natural product derived drugs in clinical trials

Reads0
Chats0
TLDR
The next few years will be critical for NP-driven lead discovery, and a concerted effort is required to identify new biologically active pharmacophores and to progress these and existing compounds through pre-clinical drug development into clinical trials.
About
This article is published in Natural Product Reports.The article was published on 2014-10-08. It has received 456 citations till now. The article focuses on the topics: Drug development.

read more

Citations
More filters
Journal ArticleDOI

Natural Products as Sources of New Drugs from 1981 to 2014

TL;DR: This contribution is a completely updated and expanded version of the four prior analogous reviews that were published in this journal in 1997, 2003, 2007, and 2012, and the time frame has been extended to cover the 34 years from January 1, 1981, to December 31, 2014, for all diseases worldwide, and from 1950 (earliest so far identified) to December 2014 for all approved antitumor drugs worldwide.
Journal ArticleDOI

Discovery and resupply of pharmacologically active plant-derived natural products: A review.

TL;DR: While the intrinsic complexity of natural product-based drug discovery necessitates highly integrated interdisciplinary approaches, the reviewed scientific developments, recent technological advances, and research trends clearly indicate that natural products will be among the most important sources of new drugs in the future.
Journal ArticleDOI

Natural product discovery: past, present, and future

TL;DR: Advances in bioinformatics, mass spectrometry, proteomics, transcriptomics, metabolomics and gene expression are driving the new field of microbial genome mining for applications in natural product discovery and development.
Journal Article

Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.:II. FERMENTATION, ISOLATION AND CHARACTERIZATION

TL;DR: Rapamycin is a new antifungal antibiotic produced by Streptomyces hygroscopicus and can be classified as a triene, highly active against various Candida species, especially Candida albicans.
Journal ArticleDOI

The E-Cadherin and N-Cadherin Switch in Epithelial-to-Mesenchymal Transition: Signaling, Therapeutic Implications, and Challenges.

TL;DR: The recent understanding of the roles of E- and N-cadherins in cancer invasion and metastasis as well as the crosstalk with other signaling pathways involved in EMT is summarized.
References
More filters
Journal ArticleDOI

Natural Products as Sources of New Drugs over the Last 25 Years

TL;DR: This review is an updated and expanded version of two prior reviews that were published in this journal in 1997 and 2003 and is able to identify only one de novo combinatorial compound approved as a drug in this 25 plus year time frame.
Journal ArticleDOI

Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010

TL;DR: This review is an updated and expanded version of the three prior reviews and adds a new designation, "natural product botanical" or "NB", to cover those botanical "defined mixtures" that have now been recognized as drug entities by the FDA and similar organizations.
Journal ArticleDOI

Natural Products as Sources of New Drugs over the Period 1981−2002

TL;DR: From the data presented, the utility of natural products as sources of novel structures, but not necessarily the final drug entity, is still alive and well, and in the area of cancer, the percentage of small molecule, new chemical entities that are nonsynthetic has remained at 62% averaged over the whole time frame.
Journal ArticleDOI

Natural products: a continuing source of novel drug leads.

TL;DR: This review traces natural products drug discovery, outlining important drugs from natural sources that revolutionized treatment of serious diseases and effective drug development depends on multidisciplinary collaborations.
Journal ArticleDOI

The evolving role of natural products in drug discovery

TL;DR: Recent technological advances that help to address issues such as the lack of compatibility of traditional natural-product extract libraries with high-throughput screening and unrealized expectations from current lead-generation strategies have led to a renewed interest in natural products in drug discovery.
Related Papers (5)